» Articles » PMID: 40003979

Review of Elevated Para-Cresol in Autism and Possible Impact on Symptoms

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2025 Feb 26
PMID 40003979
Authors
Affiliations
Soon will be listed here.
Abstract

Para-cresol (p-cresol), and its primary human metabolite p-cresol sulfate (pCS), are among the most studied gut-derived metabolites relevant to autism spectrum disorder (ASD). P-cresol is produced by bacterial modification of phenylalanine or tyrosine and is one of many potentially deleterious metabolites produced by the gut microbiota. Seventeen studies have observed p-cresol and/or p-cresol sulfate as being higher in the urine of children with autism spectrum disorder (ASD) vs. controls. P-cresol has harmful effects on the body, including within the gut, brain, kidneys, liver, immune system, and mitochondria. Some of these effects may contribute to autism and comorbid symptoms. In the gut, p-cresol acts as an antibiotic, altering the gut microbiome to favor the bacteria that produce it. In the mitochondria, p-cresol disrupts ATP production and increases oxidative stress, which is also common in autism. In the brain, p-cresol impairs neuronal development. P-cresol inactivates dopamine beta-hydroxylase, which converts dopamine to noradrenaline. P-cresol sulfate impairs kidney function and is linked to chronic kidney disease (CKD), which is more common in ASD adults. P-cresol also interferes with immune function. Three animal studies have demonstrated that p-cresol causes autism-related symptoms in mice, and that mice can be recovered by the administration of fecal microbiota transplant from healthy mice. Similarly, it was found that microbiota transplant therapy treatment in children with ASD significantly reduced p-cresol sulfate levels to normal and led to significant improvements in gastrointestinal (GI) and ASD symptoms. In summary, p-cresol and pCS likely contribute to ASD core symptoms in a substantial subset of children with ASD.

References
1.
Gryp T, Vanholder R, Vaneechoutte M, Glorieux G . p-Cresyl Sulfate. Toxins (Basel). 2017; 9(2). PMC: 5331431. DOI: 10.3390/toxins9020052. View

2.
Kang D, Adams J, Gregory A, Borody T, Chittick L, Fasano A . Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome. 2017; 5(1):10. PMC: 5264285. DOI: 10.1186/s40168-016-0225-7. View

3.
Pletinck A, Glorieux G, Schepers E, Cohen G, Gondouin B, Van Landschoot M . Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall. J Am Soc Nephrol. 2013; 24(12):1981-94. PMC: 3839540. DOI: 10.1681/ASN.2012030281. View

4.
Gevi F, Belardo A, Zolla L . A metabolomics approach to investigate urine levels of neurotransmitters and related metabolites in autistic children. Biochim Biophys Acta Mol Basis Dis. 2020; 1866(10):165859. DOI: 10.1016/j.bbadis.2020.165859. View

5.
Williams R . Sulfate Deficiency as a Risk Factor for Autism. J Autism Dev Disord. 2019; 50(1):153-161. PMC: 6946761. DOI: 10.1007/s10803-019-04240-5. View